• EN - English
  • NL - Nederlands
Parliamentary question - P-006357/2020Parliamentary question

    Pfizer patent for COVID-19 vaccine

    Priority question for written answer  P-006357/2020
    to the Commission
    Rule 138
    Mohammed Chahim (S&D)

    A COVID-19 vaccine is of vital importance to the world population. The Commission has concluded an agreement with the pharmaceutical manufacturing sector to purchase up to 300 million doses. Pfizer has indicated that it has no intention of renouncing the patent protection giving it the exclusive right to produce the vaccine. However, it is only able to produce a limited amount, while millions are being infected with COVID-19. Rolling out a vaccine quickly and on a large scale is therefore literally a matter of life and death.

    Last updated: 23 November 2020
    Legal notice - Privacy policy